Patients must meet all of the following inclusion criteria to be eligible for inclusion in
the study:
- Histologically confirmed metastatic renal cell cancer patients who have already been
using targeted therapies for up to 3 months as 3rd line treatment
- Patients older than 18 years
- Evidence of a personally signed and dated informed consent document indicating that
the patient (or a legal representative) has been informed of all pertinent aspects of
the study.
Patients meeting any of the following criteria will not be included in the study:
- Patients with contraindications for the use of the study medications
- Patients with (suspected) pregnancy or in lactation period
- Patients who are investigational site staff members directly involved in the conduct
of the trial and their family members, site staff members otherwise supervised by the
Investigator, or patients who are Pfizer employees directly involved in the conduct of
the trial.
- Participation in other studies involving investigational drug(s) (Phases 1-4) within 4
weeks before included in the current study.